Compare VYGR & MCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | MCR |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 246.2M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | MCR |
|---|---|---|
| Price | $4.29 | $6.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 582.5K | 97.0K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | ★ N/A | $16.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $5.84 |
| 52 Week High | $5.55 | $6.57 |
| Indicator | VYGR | MCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 55.09 |
| Support Level | $3.72 | $6.00 |
| Resistance Level | $4.30 | $6.37 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 92.48 | 92.31 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.